RAC1 and neoplasm: Thrombospondin 1 (THBS1) was selected, since it was significantly downregulated by all three miRNAs, similar to Ras-related C3 botulinum toxin substrate 1 (RAC1), the latter representing a potential target for cancer therapy [37], as activating RAC1 mutations can drive tumor progression [38].